- Global Pharma News & Resources

Global Dyskinesia Pipeline Insights, 2019 - Therapeutics Scenario and Growth Prospects -

The "Dyskinesia - Pipeline Insight, 2019" drug pipelines has been added to's offering.

Dyskinesia - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Dyskinesia development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Dyskinesia

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Dyskinesia

The report assesses the active Dyskinesia pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • The report provides a snapshot of the pipeline development for Dyskinesia
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Dyskinesia
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Dyskinesia
  • The report also covers the dormant and discontinued pipeline projects related to Dyskinesia

Companies Mentioned

  • Adamas Pharmaceuticals Inc
  • Addex Therapeutics Ltd
  • Advicenne SA
  • Astraea Therapeutics LLC
  • Avanir Pharmaceuticals Inc
  • Bionomics Ltd
  • Catalyst Biosciences Inc
  • Catalyst Pharmaceuticals Inc
  • Cavion LLC
  • Clevexel Pharma SAS
  • EpiVax Inc
  • Heptares Therapeutics Ltd
  • Ipsen SA
  • Merz Pharma GmbH & Co KgaA
  • Neurim Pharmaceuticals Ltd
  • Neurocrine Biosciences Inc

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 25-Jan-2019